Yuan Gui

Has grant

University of Connecticut School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Extracellular matrix protein 1 in kidney fibrotic microenvironment

Open Date: 2025-04-01

Close Date: 2028-03-31

Articles (13)

Year:

2026

Year:

2026

Year:

2026

Key Points We mapped dynamic extracellular matrix remodeling in AKI and identified microfibrillar-associated protein 2 (Mfap2) as a key repair mediator. Mfap2 drove mechanometabolic signaling through a large tumor suppressor kinase 1–mediated noncanonical Hippo pathway. The Mfap2-estrogen receptor 2-3-hydroxy-3-methylglutaryl-CoA synthase 2 circuit may be a druggable node for mitigating AKI. Background Although traditionally considered a tubule-centric disorder, AKI is increasingly recognized as involving early and active participation of fibroblasts and pericytes, the primary producer of extracellular matrix (ECM). These cells are rapidly mobilized to injury sites to support repair. Therefore, successful recovery from AKI requires not only cellular regeneration but also a finely tuned ECM, which ensures structural support and transmits essential mechanical cues. Despite its importance, the mechanistic basis by which the ECM regulates AKI repair remains incompletely understood. Methods We combined genetic and pharmacologic AKI animal models with tissue engineering approaches, data-independent acquisition–based global and phosphoproteomics, and spatial transcriptomics to profile the ECM proteome landscape of decellularized kidney matrix scaffolds after injury, uncover mechanometabolic pathways driving repair, and evaluate potential therapeutic strategies. Results We generated a comprehensive proteomic map of the AKI kidney matrix scaffold and highlighted microfibrillar-associated protein 2 (Mfap2) as a key core matrisome component primarily derived from fibroblasts and pericytes. Mfap2 loss disrupted kidney architecture and metabolic homeostasis, aggravating AKI severity. Global proteomics revealed that Mfap2 deficiency downregulated tubular 3-hydroxy-3-methylglutaryl-CoA synthase 2 (Hmgcs2) through estrogen receptor 2 (Esr2)–mediated transcriptional repression and increased protein succinylation. Phosphoproteomic and spatial transcriptomic analysis showed that Mfap2 loss altered mechanotransduction, leading to mitogen-activated protein kinases hyperactivation and upregulation of large tumor suppressor kinase 1 in tubular cells, without affecting integrin receptor activity. Although large tumor suppressor kinase 1 is a key Hippo pathway kinase, its activation suppressed Esr2 transcription independently of the canonical yes-associated protein/transcriptional coactivator with PDZ-binding motif effectors and without affecting Esr2 degradation. Therapeutically, Esr2 agonist restored Hmgcs2 levels and improved kidney function in Mfap2 -deficient models. Conclusions Mfap2, a fibroblast/pericyte-derived core matrisome component, preserved kidney architecture and supported tubular ketogenesis by regulating Hmgcs2 via Esr2 in the AKI microenvironment.

Year:

2025

Year:

2025

Year:

2025

Sepsis is a life‐threatening condition that occurs when the body responds to an infection but subsequently triggers widespread inflammation and impaired blood flow. These pathologic responses can rapidly cause multiple organ dysfunction or failure either one by one or simultaneously. The fundamental common mechanisms involved in sepsis‐induced multiple organ dysfunction remain unclear. Here, employing quantitative global and phosphoproteomics, we examine the liver's temporal proteome and phosphoproteome changes after moderate sepsis induced by cecum ligation and puncture. In total, 4593 global proteins and 1186 phosphoproteins according to 3275 phosphosites were identified. To characterize the liver–kidney comorbidity after sepsis, we developed a mathematical model and performed cross‐analyses of liver and kidney proteome data obtained from the same set of mice. Beyond immune response, we showed the commonly disturbed pathways and key regulators of the liver–kidney comorbidity are linked to energy metabolism and consumption. Our data provide open resources to understand the communication between the liver and kidney as they work to fight infection and maintain homeostasis.

Year:

2024

Year:

2024

Background: Acute kidney injury (AKI) and chronic kidney disease (CKD) share a fundamental disruption: metabolic dysfunction. Methods: A literature review was performed to determine the metabolic changes that occur in AKI and CKD as well as potential therapeutic targets related to these changes. Results: In AKI, increased energy demand in proximal tubular epithelial cells drives a shift from fatty acid oxidation (FAO) to glycolysis. Although this shift offers short-term support, it also heightens cellular vulnerability to further injury. As AKI progresses to CKD, metabolic disruption intensifies, with both FAO and glycolysis becoming downregulated, exacerbating cellular damage and fibrosis. These metabolic alterations are governed by shifts in gene expression and protein signaling pathways, which can now be precisely analyzed through advanced omics and histological methods. Conclusions: This review examines these metabolic disturbances and their roles in disease progression, highlighting therapeutic interventions that may restore metabolic balance and enhance kidney function. Many metabolic changes that occur in AKI and CKD can be utilized as therapeutic targets, indicating a need for future studies related to the clinical utility of these therapeutics.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Yansheng Liu

Associate Professor (Secondary)

Yale University School of Medicine

UNITED STATES
View details

Dong Zhou

-

UNITED STATES
View details

Yanbao Yu

Director of Proteomics

University of Delaware

UNITED STATES
View details